IDE397 + docetaxel

IDE397 + docetaxel is an investigational combination therapy consisting of **IDE397**, a potent and selective small molecule inhibitor of methionine adenosyltransferase 2 alpha (MAT2A), and **docetaxel**, a well-established taxane chemotherapy. IDE397 targets MAT2A, a synthetic lethal vulnerability in solid tumors with *methylthioadenosine phosphorylase* (MTAP) deletion, aiming to disrupt methionine metabolism and hinder tumor growth. **Docetaxel** is a chemotherapeutic agent that stabilizes microtubules and inhibits cell division, widely used for the treatment of various solid tumors including lung, breast, and prostate cancers. The combination is being studied in clinical trials for MTAP-deleted advanced or metastatic solid tumors, leveraging the potential synergistic effects of tumor-specific metabolic inhibition alongside cytotoxic chemotherapy[3]. As of current data, the combination's efficacy and safety profile are being evaluated in early-phase (Phase 1) clinical studies[3].